ImmuPharma (LON:IMM) Shares Down 6.3% - Here's Why

Key Points

• ImmuPharma's stock fell 6.3% during trading, closing at GBX 11.60 ($0.15) after reaching a low of GBX 10.70 ($0.14), with a significant trading volume decline of 53% compared to average sessions.
• The company's market capitalization is approximately £58.32 million, and it has reported an earnings per share (EPS) of GBX (0.38).
• ImmuPharma specializes in peptide-based therapeutics for autoimmune diseases, with its lead program P140 (Lupuzor™) targeting Lupus treatment.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price fell 6.3% during trading on Saturday . The stock traded as low as GBX 10.70 ($0.14) and last traded at GBX 11.60 ($0.15). 3,961,091 shares traded hands during mid-day trading, a decline of 53% from the average session volume of 8,360,403 shares. The stock had previously closed at GBX 12.38 ($0.16).

ImmuPharma Stock Performance

The company has a market capitalization of £58.32 million, a PE ratio of -13.03 and a beta of 1.53. The business's 50-day moving average is GBX 8.95 and its 200-day moving average is GBX 4.69.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.